CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 2.25
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company that researches, develops, manufactures and markets products for the treatment of human diseases. With a market cap of over $138bn it is one of Australia's top three largest index weights. The former Commonwealth Serum Laboratory listed in June 1994 and has generated an average annual return of 28% since (up until mid-2020). CSL is the world's largest collector of plasma and the second largest producer of vaccines.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$137.55

16 Apr
2026

-1.890

OPEN

$140.50

-1.36%

HIGH

$140.98

1,349,509

LOW

$136.38

TARGET
$202.906 47.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CSL: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 951.7 xxx
DPS (cps) 469.8 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 14.4 xxx
Dividend Yield 3.4% xxx
Div Pay Ratio(%) 49.4% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.36%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.97

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 09/09 - (franking ex-div 248.50c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx957.6
DPS All xxxxxxxxxxxxxxx452.2
Sales/Revenue xxxxxxxxxxxxxxx23,825.3 M
Book Value Per Share xxxxxxxxxxxxxxx6,093.1
Net Operating Cash Flow xxxxxxxxxxxxxxx5,498.5 M
Net Profit Margin xxxxxxxxxxxxxxx19.46 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx16.70 %
Return on Invested Capital xxxxxxxxxxxxxxx10.46 %
Return on Assets xxxxxxxxxxxxxxx7.92 %
Return on Equity xxxxxxxxxxxxxxx16.70 %
Return on Total Capital xxxxxxxxxxxxxxx12.77 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx2,456.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1,227 M
Long Term Debt xxxxxxxxxxxxxxx16,318 M
Total Debt xxxxxxxxxxxxxxx17,545 M
Goodwill - Gross xxxxxxxxxxxxxxx12,306 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx3,291 M
Price To Book Value xxxxxxxxxxxxxxx3.93

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1,541.0 M
Capex % of Sales xxxxxxxxxxxxxxx6.47 %
Cost of Goods Sold xxxxxxxxxxxxxxx12,186 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx5,415 M
Research & Development xxxxxxxxxxxxxxx2,098 M
Investments - Total xxxxxxxxxxxxxxx310 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.6

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

24/03/2026

1

Buy

$235.00

70.85%

CSL has reported a rapid uptake of Andembry since the launch in mid 2025 with more than one thousand patients on the therapy. UBS estimates this represents around 15% of patients on prophylactic treatment across the major markets where it has been approved.

While the launch trajectory is encouraging, investor attention is on the execution risk embedded in FY26 guidance, the broker points out, particularly the required lift in second half sales.

While acknowledging the risk UBS expects cost control will support earnings delivery even if sales momentum falls short. Buy rating and $235 target.

FORECAST
UBS forecasts a full year FY26 dividend of 443.41 cents and EPS of 1059.67 cents.
UBS forecasts a full year FY27 dividend of 465.95 cents and EPS of 1158.88 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

11/03/2026

1

Buy

$180.00

30.86%

If CSL can achieve FY26 guidance where Andembry features more than cost reductions then Canaccord Genuity considers this will be a win and one which the company's narrative can be "re-consolidated".

The product is the best internally developed example from the company's R&D since Idelvion, the broker contends, and CSL badly needs a winner. Buy rating. Target is $180.
Access Extra Coverage Research History >

CSL STOCK CHART

FNArena News on CSL

1
Australian Broker Call *Extra* Edition – Apr 13, 2026

Apr 13 2026 - Daily Market Reports
2
Next Week At A Glance – 13-17 Apr 2026

Apr 10 2026 - Weekly Reports
3
Rudi’s View: Strategists Touting Opportunities

Apr 02 2026 - Rudi's View
4
Rudi’s View: Make Today’s Crisis Your Opportunity

Mar 25 2026 - Rudi's View
5
Next Week At A Glance – 23-27 Mar 2026

Mar 20 2026 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
2
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
3
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
4
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
5
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
6
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
7
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
8
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
9
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
10
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps